Citations

Clear

14 citation(s) found for "Hildebrand, F L".

Evaluation of Interventions for Cognitive Symptoms in Long COVID
Koltai, Deborah, Laskowitz, Daniel T. , Wisnivesky, Juan P., Federman, Alex D. , Silverstein, Adam M. , Lokhnygina, Yuliya, Haddad, Michelle M., Mahncke, Henry W. , Vleet, Tom Van, Huang, Rong , Cox, Wendy C., Terry, Diana, Karwowski, Jeannie, McCray, Netia, Lin, Jenny , Singh, Upinder , Geng, Linda N. , Reece, Rebecca , Moy, James N., Arvanitakis, Zoe , Parthasarathy, Sairam , Patterson, Thomas F., Gupta, Aditi , Parsonnet, Jeffrey, Kiriakopoulos, Elaine T. , Mullington, Janet , Jolley, Sarah E. , Shah, Nirav S. , Morimoto, Sarah Shizuko , Lee‐Iannotti, Joyce , Isache, Carmen, Frontera, Jennifer , O’Steen, Ashley, James, Melissa, Harper, Barrie, Zimmerman, Kanecia O. , Lawler, Andrew , Johnson, Brandon M. , Pitsch, Chloe E. , Feuerriegel, Elen , McKeehan, Jeffrey, Molden, Joie, Reid, Kayleigh M., Dowling, Sarah , Wodushek, Thomas, Canton, Diara, Turut, Dilara, Sheppard, Ethan , Scott‐Sutherland, Jennifer, Shaughnessy, Lynn, Beck, Michelle L. , Heisey, Sabrina, Katragadda, Vaishanvi, Yusuff, Amidat, Perlack, Amy, Merisme, Christie, Krause, David, Schulte, Duncan, Dupre, Fabiola, Sanchez, Gina A. Montealegre , Asupoto, Olanike, Simmons, Quinneil, Schroeder, Ryan W. , Timlin, Shannon, Devis, Ycar, Carter, Della, Caceres, Leomaris Caba, Rodríguez, Miguel Grande, Alvarez, Zariya , Yakubov, Amin , Engelson, Celia, Reyes, Michael, Youkhana, Alvin, Jennings, Cheryl , Naquiallah, Dina, Behun, Dylan , Stephen, Ellen, Timm, Emily , Bilimoria, Farrah, Li, Grace , Stricker, Thomas, Michelle, Kang, Minnie, Suarez, Rebeca Tojo, Carmona, Tania, Ramírez, Ana, Kadubek, Grace, Baker, Aileen, Romo-Serna, Andrea, Predki, Barbara, Leman, Cindy, Panhans, Cristina, Roth, Genevieve E., Rudraraju, Gowrisree , Miller, Hannah , DeLisa, Julie A., Williams, Kat, Woodson, Kimberly S., Jennette, Kyle J. , Villanueva, Laura, Norwick, Maria, Martínez, M. T., Rowley, Matt, Carrithers, Michael D. , Pliskin, Neil H. , Pérez, Nicolás , Durkin, Nicole M., Maniar, Nikita, Beety, Rachel, Daspgupta, Raktima, Ramchandran, Ramaswamy, Jaramillo, R., Hasek, Sharon, Macías, S Aguirre, Schuh, Tina , Ialacci, Sarah, Bailey, Christopher , Labbato, Danielle, Hautmann, Amanda , Smith, Beth, Nath, Dia, Meyer, Jessica , DiFrancesco, Kathryn, Pettinato, Kimberly, Curtis, Lynette, Daher, Joviane , Koberssy, Ziad , Mavar, Caleb, Andrefsky, John, Merheb, Alexander, Hernandez, Carla, Baissary, Jhony , Atieh, Ornina , Pereira, Carol, Carpenter, Deborah, Raynor, Jennifer , Brunton, Kristine, Podgoreanu, Andreea, Bunch, P. C., O’Brien, Sean M. , Dickey, Sheila, McNulty, Steven E., Gajjar, Varsha, Neale, Alec C. , Cohen, Cari, Geary, Elizabeth, Campanella, Franco, Anderson, Kirsten, Prestige, Laura, Guidotti-Breting, Leslie, Biewer, Megan, Morton, Melissa , Mathenia, Nicholas, Adeyemi, Oluwadamilola A. , Hengst, Samanike, Ning, Wei , Vanderloo, Adam, Caplan, Amanda, Chen, July, Acree, Mary Ellen , Nakhate, Mukund, Dan, Zaw Nu, Pk, Switzer, Aryal, Shambhu , Sanchez, Jessica, Sims, Luke, Ferdinand, Rebecca , Mammadova, Mehriban, Grimes, Carolyn Z. , Vidales, Elizabeth, Pham, Hau , Nielsen, Laura, Keller, Maryjane, Uruba, Syeda, Hernandez, Maria, Patel, Bela , Umana-Sanchez, Virginia, Pak, Chong, Gainer, Jeffery, BURR, R, Trapuzzano, Ashleigh, Celso, Brian G. , Bienkowski, Grace, Bowman, Jennifer, Verdecia, Jorge , Zerwekh, Kathryn, Serrano, Liliana , Marotz, Meghan, Propp, Piper, Sarig, Yonatan , Murphy, Annie, Comfort, Brandon, Torres, Iri, Klein, Jeffrey A. , Walker, John, Moore, John J., Tempest-Browning, Lisa, Arain, Mudassar, Kemp, Pamela, Sullivan, Samantha, Way, Sonja, Chevalier, Jessica, Sykes, Carly, Kruck, Carrie L., Sackett, L. W., Bang, Claire, Hynes, Mary, Gallagher, Torrey L., Childers-Kakos, Margaret, Zia, Ahmad, South, AP, Oravets, Anne, Ferreyra, Carolyn, Glaze, Chad, Villanueva, Daphne-Dominique , Blystone, Erica, Pritchard, Jane, Alyward, Laura, Cooper, Melissa, Chidester, Michelle, Alderson, R. Matt , Clark, Renee D., Hodder, Sally , Sarwari, Arif R, Juskowich, Joy, Welch, Shelly, Civil, Alyssa, Bendl, Ashley, Dicker, Elisa, Hanson, Hannah, Viola, Heather, Morinigo, Janice, Pantaleon, Karisma, Marcon, Kathryn, Stone, Kimberly, Stewart, Kiwan, Evo-Ortega, Lorraine, McVeety, Megan, Guliyeva, Sabina , Watson, Eric , Pehel, Shayna, Ko, Tim, Caropolo, Leah, Kocas, H. Deniz , O’Donnell, Andrew, Saperia, Corey , Thai, Daniel, Pathak, Divya , Keller, Jennifer M. , Olszewski, Kelly, Clinton, Kimberly, Cherian, Kirsten , Dutton, L M, Elepano, Ma, Mohapatra, Sukanya , Chen, Ting , Wroolie, Tonita, Leang, Zenita, Shashidhar, Sumana, Nguyen, T L, Ravisankar, Ashwath, Weiden, Brycie, Bolliger, Dawn, Glesne, Heather, Dixon, Jennifer , Chebrolu, Praneeth, Gazali, Zarine, Hurst, Whitney, Fry, Avery, Murthy, Ganesh, Grischo, Garrett, Erickson, Heidi L. , Gomez, Isaias, Copeland, Jacquelynn, Galaz, Judy, Autry, Lynn, DiLise-Russo, Marjorie, Marshell, Nikki, Borwege, Sabine, Vadovicky, Sheila, Marsh, Stephanie, Hartley, William, Murtagh, Linda, Kennedy, Anna, Meltzer-Christensen, Annie, Stringham, Caitlyn, Gaskin, Ella, Judd, Melissa, Côté, Sarah , Mahasenan, Shreya, Bjorklund, Todd, Farner, Cheryl E., Taylor, Barbara S. , Soileau, Bridgette, Cote, Cyrena , Hromas, Gabrielle A., Scholler, Irma, Longoria, Lisa, Heard, Patricia, Jones, Johnnie, Tragus, Robin , Harris, Maya, Pinones, Alexis, Anderson, Alyssa , Hastings, Gabrielyd, Courtright, jessica, Jayakumar, Madhumita, Fischer, M, Solis, Pamela, Harteloo, Alex, Elias-Warren, Anna, Nguyen, Daniel , McDonald, Dylan , Rau, Holly , Mernaugh, Jean, Pagulayan, Kathleen F. , Watanabe, Kino, Huden, Kristen, Peabody, Laurel, Mei, Tiffany, Ogunwuyi, Catherine, Cobbina, Esther, Sankar, Ian, Nguyen, Lisa , Fromm, N., Arnold, R. Douglas, Ogu, Stephanie, Yuan, Ying , Ibrahim, Homam , Szum, Izabella, Patel, Jignesh, Sultan, Sonia, Jazayeri, Yasmin, Anderson, Betty Lise, Muñoz, Isabel , Rhys, Logan, Vane, Ryan, Kim, Jessica , Diaz, Leticia M., Yee, Nathan, Gruhn, Robert, Browngoetz, Sarah, Johnson, Elisha, Chand, Arista , Bottrill, Kenneth , Henderson, Kymberly, Johnson, DeArmond, Richard C., Hughes, Trina, Silverstein, A , Silverstein, Adam P , Frontera, Jennifer , Geng, Linda N. , Knopman, David S. , Becker, Jacqueline , Charvet, Leigh , Pilloni, Giuseppina , Huang, Rong, Cox, Wendy, Karwowski, Jeannie, McComsey, Grace A. , Chu, Helen Y. , Ostrosky‐Zeichner, Luis , Fong, Tamara G. , Killgore, William D. S. , Dwyer, Brigid C. , Stringer, William W. , Krishnan, Jerry A , James, Melissa, Johnson, Brandon, Erlandson, Kristine M. , Dowling, Sarah, Hauser, Kristine , Doyle, Michael, Beck, Michelle, Tran, Anh, Altaras, Caroline , Sanchez, Gina, Krengel, Maxine , Ly, Monica T. , Asupoto, Olanike, Schroeder, Ryan, Rodriguez, Miguel, González, David Andrés , Torres, Jimena, García, Maria Luisa , Carrera, Laura, Rutherford, Melissa, Perez, Nicolas, Jaramillo, Ruthie, Smith, Beth, Walkup, Kevin, Scott, Sarah , Mavar, Caleb B., Carpenter, Deborah, Bunch, Pyper, Brown, Richard, Escobar, Carolina, Campanella, Franco, Mathenia, Nicholas, Glickman, Michael S. , Sims, Luke A., Pham, Hoai Phuang, Lopez, John, Hernandez, Maria, Lin, Matthew Junda , Gainer, Jeffery, Brown, Gina , Klein, Jeffrey, Reed, Jessica, Walker, John, Sackett, Lisa, Kaden, Sarah J. , Childers-Kakos, Margaret G, South, Amy, Blystone, Erica, Cooper, Melissa, Alderson, Rachael, Clark, Renee, Bardes, James M. , Hanson, Hannah, Loizos, Maria , Caropolo, Leah J., Fernandez, Luis, Keller, Jennifer, Lin, Rebecca, Brown, Daniel, Dixon, Jennifer, James, Michelle, Kala, Mrinalini , Smith, Ryan S. , Mahasenan, Shreya, Johnson, Hillary, Anderson, Alyssa, Hernandez, Jessica, Sullivan, Michael, Nguyen, Helen , Logue, Jennifer, Mei, Tiffany, Arnold, Rowan, Szum, Izabella , Hatlen, Timothy J. , Anderson, Betty, Munoz, Isabel, Wright, Matthew, Diaz, Leticia, DeCato, Thomas W. , Ortiz, Ernesto, Hildebrand, Lindsey L. , DeArmond, Richard

Mayo Clinic

JAMA Neurology | November 10, 2025 | Volume: 83 | Issue: 1 | Pages: 49

10.1001/jamaneurol.2025.4415 | PMID 41212544 Get It

Importance Treatment for cognitive dysfunction due to postacute sequelae of long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection) remains a significant unmet need. Objective To test evidence-based rehabilitation strategies for improving cognitive symptoms in persons with long COVID. Design, Setting, and Participants This was a 5-arm, multicenter, randomized clinical trial of 3 remotely delivered interventions conducted between August 17, 2023, and June 10, 2024. The study took place at 22 trial sites and included the screening of individuals with cognitive long COVID. Interventions Participants were randomized to 1 of 5 arms: adaptive computerized cognitive training (BrainHQ [Posit Science]), cognitive-behavioral rehabilitation involving both group and individual counseling sessions (PASC-Cognitive Recovery [PASC-CoRE]) paired with BrainHQ, and transcranial direct current stimulation (tDCS) paired with BrainHQ. Two comparator arms were included as follows: unstructured computer puzzles and games (active comparator) and sham tDCS paired with BrainHQ. The interventions occurred 5 times per week over 10 weeks. Main Outcomes and Measures Cognitive and behavioral in-person assessments were performed at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention. The primary outcome measure was the modified Everyday Cognition Scale 2 (ECog2) completed at the end of the intervention compared to the baseline visit based on participant self-report looking back over the prior 7 days. Results A total of 378 individuals were screened, from which there were 328 participants (median [IQR] age, 48.0 [37.0-58.0] years; 241 female [73.5%]; race: 15 Asian [4.6%], 47 Black [14.3%], and 235 White [71.6%]; ethnicity: 52 Hispanic [15.9%]). None of the 3 active interventions demonstrated benefits on the modified ECog2 in the intention-to-treat population by the end of the intervention period. The adjusted differences in mean change were 0.0 (95% CI, −0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (95% CI, −0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (95% CI, −0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (95% CI, −0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. Secondary participant-reported outcomes and neuropsychological tests showed no differential benefits for any treatment arm. All 5 arms demonstrated some improvements over time on the modified ECog2 and on secondary outcomes. There were no serious adverse events attributable to the interventions. Conclusions and Relevance This phase 2 randomized clinical trial failed to demonstrate differential benefits for online cognitive training, a structured cognitive rehabilitation program, and tDCS for cognitive long COVID. Trial Registration ClinicalTrials.gov Identifier: NCT05965739 .
P-1650. Clinical Outcomes among Patients Prescribed Suboptimal Antibiotic Therapy on Discharge to Nursing Homes
Short, Emily K. , Chan, Dominic , Hildebrand, Andrea , Nguyen, Thuan , Zhou, Michelle H, Santos, Emily , Ham, YoungYoon , Shephard, Emily, McCracken, Caitlin M. , Noble, Brie N. , Crnich, Christopher J. , Zhou, Michelle H, McGregor, Jessina C. , Jolles, Sally A. , Bearden, David T. , Izumi, Shigeko , Furuno, Jon P.

Mayo Clinic

Open Forum Infectious Diseases | January 29, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofae631.1816 Get It

Abstract Background Little is known regarding outcomes for patients prescribed antibiotics on discharge from the hospital to nursing homes (NHs). We quantified the association between suboptimal antibiotic prescribing and clinical outcomes at discharge to NHs. Methods This was a multicenter, retrospective cohort study of adult (age >18 years) patients prescribed systemic antibiotics on discharge from 9 acute care hospitals in Oregon, Washington, and Wisconsin to a NH from 2016 – 2018. Study data were electronically extracted from hospital and NH electronic health records and supplemented with chart review. Suboptimal antibiotic therapy was determined by an infectious disease pharmacist or physician using clinical information (e.g., antibiotic regimen, indication, and culture results) available at discharge. Outcomes included emergency department (ED) visits, hospital readmissions, or Clostridioides difficile infection (CDI) within 30 days of hospital discharge. Comparison of outcomes between patients with suboptimal and non-suboptimal antibiotic therapy were tested by chi-squared tests. Results Among 280 included patients, mean (SD) age was 76.0 (11.5) years, 35.7% (n=100) were male, and median (IQR) inpatient length of stay was 6 (4-9) days. The most prevalent antibiotic indications were urinary tract infections (n =109, 38.9%), lung indications (n=60, 21.4%), and prophylaxis (n=29, 10.4%). Among 317 antibiotic prescriptions, the most frequently prescribed antibiotic classes were cephalosporins (n=83, 29.6%), fluoroquinolones (n=57, 20.4%), and beta-lactam/beta-lactamase-inhibitors (n=40, 14.3%). Fifty-eight patients (20.7%) were prescribed suboptimal antibiotic therapy on hospital discharge. There were no significant differences in the frequency of 30-day ED visits (14% vs 11%, p=0.76) or hospital readmission (19% vs 18%, p=0.94) between patients prescribed and not prescribed suboptimal antibiotics; however, suboptimal antibiotics were significantly associated with CDI within 30 days of discharge (10% vs 2%, p=0.01). Conclusion Suboptimal antibiotic prescribing on discharge to NHs was associated with increased risk of CDI within 30 days of discharge. This finding may inform interventions to improve antibiotic prescribing on discharge to NHs. Disclosures YoungYoon Ham, PharmD, Gilead: Honoraria Jon P. Furuno, PhD, Merck & Co., Inc: Grant/Research Support
Investigating the link between frailty and outcomes in geriatric patients with isolated rib fractures
Mohseni, Shahin , Forssten, Maximilian Peter , Ismail, Ahmad Mohammad , Sarani, Babak , Ribeiro, Marcelo AF, Mohammad Ismail, Ahmad , Sarani, Babak , Mohseni, Shahin , Cao, Yang , Hildebrand, Frank

Mayo Clinic

Trauma Surgery & Acute Care Open | February 8, 2024 | Volume: 9 | Issue: 1 | Pages: e001206

10.1136/tsaco-2023-001206 | PMID 38347893 Get It

Background Studies have shown an increased risk of morbidity in elderly patients suffering rib fractures from blunt trauma. The association between frailty and rib fractures on adverse outcomes is still ill-defined. In the current investigation, we sought to delineate the association between frailty, measured using the Orthopedic Frailty Score (OFS), and outcomes in geriatric patients with isolated rib fractures. Methods All geriatric (aged 65 years or older) patients registered in the 2013–2019 Trauma Quality Improvement database with a conservatively managed isolated rib fracture were considered for inclusion. An isolated rib fracture was defined as the presence of ≥1 rib fracture, a thorax Abbreviated Injury Scale (AIS) between 1 and 5, an AIS ≤1 in all other regions, as well as the absence of pneumothorax, hemothorax, or pulmonary contusion. Based on patients’ OFS, patients were classified as non-frail (OFS 0), pre-frail (OFS 1), or frail (OFS ≥2). The prevalence ratio (PR) of composite complications, in-hospital mortality, failure-to-rescue (FTR), and intensive care unit (ICU) admission between the OFS groups was determined using Poisson regression models to adjust for potential confounding. Results A total of 65 375 patients met the study’s inclusion criteria of whom 60% were non-frail, 29% were pre-frail, and 11% were frail. There was a stepwise increased risk of complications, in-hospital mortality, and FTR from non-frail to pre-frail and frail. Compared with non-frail patients, frail patients exhibited a 87% increased risk of in-hospital mortality [adjusted PR (95% CI): 1.87 (1.52-2.31), p<0.001], a 44% increased risk of complications [adjusted PR (95% CI): 1.44 (1.23-1.67), p<0.001], a doubling in the risk of FTR [adjusted PR (95% CI): 2.08 (1.45-2.98), p<0.001], and a 17% increased risk of ICU admission [adjusted PR (95% CI): 1.17 (1.11-1.23), p<0.001]. Conclusion There is a strong association between frailty, measured using the OFS, and adverse outcomes in geriatric patients managed conservatively for rib fractures.
International validation of the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score in heart failure
Adamopoulos, Stamatis , Miliopoulos, Dimitrios , Piotrowicz, Ewa , Snoek, Johan A. , Panagopoulou, Niki , Niederseer, David , Mazaheri, Reza , Ma, Jing , Chen, Yundai , Popović, Dejana , Seferović, Petar , Girola, Davide, Metra, Marco , Rosano, Giuseppe , Piepoli, Massimo , Corrà, Ugo , Agostoni, Piergiuseppe , Metra, Marco , Nanas, Serafim , Corrà, Ugo , Coats, Andrew J.S. , Volterrani, Maurizio , Apostolo, Anna , Campodonico, Jeness , Salvioni, Elisabetta

Mayo Clinic

European Journal of Preventive Cardiology | June 8, 2023 | Volume: 30 | Issue: 13 | Pages: 1371-1379

10.1093/eurjpc/zwad191 | PMID 37288595 Get It

Abstract Aims Current European heart failure (HF) guidelines suggest the use of risk score: among them, the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score has demonstrated to be one of the most accurate. However, the risk scores are still poorly implemented in clinical practice, also due to the lack of strong evidence regarding their external validation in different populations. Thus, the current study was designed as an external validation test of the MECKI score in an international multicentre setting. Methods and results The study cohort consisted of patients diagnosed with HF with reduced ejection fraction (HFrEF) across international centres (not Italian), retrospectively recruited. Collected data included demographics, HF aetiology, laboratory testing, electrocardiogram (ECG), echocardiographic findings, and cardiopulmonary exercise testing (CPET) results as described in the original MECKI score publication. A total of 1042 patients across 8 international centres (7 European and 1 Asian) were included and followed up from 1998 till 2019. Patients were divided according to the calculated MECKI scores into three subgroups: (i) MECKI score &lt;10%, (ii) 10–20%, and (iii) ≥ 20%. Survival analysis comparison among the three MECKI score subgroups showed a worse prognosis in patients with higher MECKI score value: median event-free survival times were 4396 days for MECKI score &lt;10%, 3457 days for 10–20%, and 1022 days for ≥20% (P &lt; 0.0001). Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) were like those reported in the original internal validation studies. Conclusion In patients diagnosed with HFrEF, the power of the MECKI score was confirmed in terms of prognosis and risk stratification, supporting its implementation as advised by the HF guidelines.
A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling
Luo, Zhenghua , Ziesmer, Steven C., Price-Troska, Tammy, Lin, Wai, Hostager, Bruce S. , Ansell, Stephen M. , Novak, Anne J. , Hildebrand, Joanne M. , Manske, Michelle K. , Price-Troska, Tammy, Slager, Susan L. , Witzig, Thomas E. , Cerhan, James R. , Bishop, Gail A.

Mayo Clinic

Blood | October 12, 2019 | Volume: 116 | Issue: 21 | Pages: 468-468

10.1182/blood.v116.21.468.468 Get It

Abstract Abstract 468 The requirement for BAFF and BAFF-R in normal human and murine B cells is well studied, but there is also significant evidence to suggest that BAFF plays an important role in malignant B cell proliferation and survival. Serum BAFF levels are elevated in patients with non-Hodgkin lymphoma (NHL) and high BAFF levels correlate with aggressive disease and a poor response to therapy. There is also increasing genetic evidence suggesting an association between the development of human disease and genetic variation in genes encoding BAFF and its receptors. Mutations in TNFRSF13B (TACI) were identified in patients with familial common variable immunodeficiency (CVID) and IgA deficiency and we have found that single nucleotide polymorphisms (SNP) in TNFSF13B (BAFF) are associated with elevated BAFF levels and risk for developing NHL. To build upon these findings we sequenced BAFF and its receptors; TNFSF13B, TNFRSF13B, TNFRSF17(BCMA), and TNFRSF13C (BAFF-R) in NHL patients to identify novel genetic variants that may be associated with NHL risk. Among 40 individual samples (20 controls and 20 follicular lymphoma (FL) cases) that were bi-directionally sequenced we identified a heterozygous cytosine to thymidine transition in 1 patient specimen at position 475 (C475T) of TNFRSF13C. The C475T transition encodes a missense substitution of tyrosine for histidine in codon 159 (H159Y) in the highly conserved cytoplasmic tail of BAFF-R, adjacent to the TRAF3 binding motif PVPAT. We next expanded our analysis of BAFF-R H159Y and analyzed NHL tumor biopsies for the presence of the mutation. 4/41 (10%) follicular lymphomas (FL), 2/42 (5%) diffuse large B cell lymphomas, 1/22 (5%) lymphoplasmacytic lymphomas (LPL), and 1/24 (4%) mucosal associate lymphoid tissue lymphomas carried the heterozygous mutation. The BAFF-R H159Y mutation was not detected in any of the normal control DNA from healthy donors (n=100). Given its close proximity to the TRAF3 binding site in the cytoplasmic domain of BAFF-R we first wanted to determine if the H159Y mutation altered BAFF induced signaling. We generated cell lines that express HA-tagged wildtype BAFF-R, BAFF-R with the H159Y mutation, or BAFF-R with an ablated TRAF3 binding site as a negative control. Analysis of cells expressing H159Y BAFF-R demonstrates that this mutation results in increased BAFF-R-mediated NFκB1 and NF-κB2 activation. The enhanced signal activated by BAFF-R H159Y is coupled with a several fold increase in TRAF3, TRAF2, and TRAF6 recruitment to BAFF-R and increased IgM production. We further demonstrate that recruitment of TRAF6 to BAFF-R is not unique to the mutant H159Y BAFF-R, but is also an important and necessary feature of BAFF-R signaling in normal B cells. Collectively, our data identify a novel lymphoma-associated mutation in BAFF-R and describe exciting new aspects of BAFF-R signaling that are important for understanding normal B cell homeostasis and function, as well as pathogenic BAFF-R contributions to human disease. Disclosures: No relevant conflicts of interest to declare.
Abstract 221: Inherited variants at 3q13.33 and 3p24.1 influences risk of diffuse large B-cell lymphoma
Hildebrand, Michelle, Berndt, Sonja I. , Ghesquières, Hervé , McKay, James , Nieters, Alexandra, Cox, D. F., Monnereau, Alain , Brooks‐Wilson, Angela , Lan, Qing , Jackson, Rebecca D. , Crouch, Simon , Wu, Xifeng , Smedby, Karin E. , Salles, Gilles , Skibola, Christine F., Rothman, Nathaniel , Brooks-Wilson, Angela R , Salles, Gilles A , Kleinstern, Geffen , Vijai, Joseph , Wang, Sophia , Cox, David, Melbye, Mads , Teras, Lauren R. , Purdue, Mark P. , Vajdic, Claire M. , Albanes, Demetrius , Zeleniuch‐Jacquotte, Anne , Zhang, Yawei , Slager, Susan L. , Chanock, Stephen Jacob , Cerhan, James R.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 221-221

10.1158/1538-7445.am2018-221 Get It

Abstract Background: We previously identified 5 SNPs at 4 susceptibility loci for diffuse large B-cell lymphoma (DLBCL) in individuals of European ancestry through a large genome-wide association study (Cerhan et al, Nat Gen 2014;46:1233-8); however, much of the heritability remains unexplained. To further elucidate genetic susceptibility to DLBCL, we sought to validate 2 loci at 3q13.33 and 3p24.1 that were suggestive in the original report. Methods: We selected two SNPs rs9831894 (3q13.33) and rs6773363 (3p24.1) for de novo replication from studies at the Mayo Clinic, MD Anderson, and Memorial Sloan Kettering. Logistic regression was used to estimate odds ratios (ORs), using a log-additive model, and adjusting for age, gender and significant eigenvectors for each genotyping center separately. For both SNPs, we then conducted a meta-analysis of all replication studies (n=3) and our original GWAS studies (n=4), encompassing in total 5662 cases and 9237 controls for rs9831894, and 5510 cases and 12,817 controls for rs6773363. Meta-analysis was conducted using the fixed-effects inverse variance method based on the β estimates and standard errors from each study. Results: In a meta-analysis of the 4 original GWAS scans (3856 cases and 7666 controls), rs9831894 (MAF=0.40) was associated with DLBCL risk (OR=0.84, P=4.52 x 10-9) and this replicated in a meta-analysis of the 3 studies with de novo genotyping (OR=0.80, P=4.17 x 10-5); the overall meta-analysis showed a strong association with DLBCL risk (OR=0.83, P=3.62 x 10-13). This locus maps near a plausible candidate gene, CD86, a protein coding gene and a member of the immunoglobulin superfamily that encodes a type I membrane protein. Binding of CD86 with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response, while binding of CD86 with CD28 antigen is a costimulatory signal for activation of the T-cell. In a meta-analysis of the same 4 GWAS scans, rs6773363 (MAF=0.45) was tentatively associated with DLBCL risk (OR=1.17, P= 3.68 x 10-7) and this replicated in a meta-analysis of the studies with de novo genotyping (OR=1.27, P=3.78 x 10-7); the overall meta-analysis showed a strong association with DLBCL risk (OR=1.20, P=2.31 x 10-12). This locus also maps near a plausible candidate gene, eomesodermin (EOMES), a transcription factor crucial for embryonic development of the central nervous system and also putatively involved in T-cell differentiation in viral infection defense. Conclusion: In this follow-up analysis of our initial GWAS, we have identified two additional loci associated with risk of DLBCL, the most common lymphoma subtype. These loci provide additional evidence for the role of immune function in the etiology of DLBCL. Citation Format: Geffen Kleinstern, Michelle Hildebrand, Vijai Joseph, Sonja I. Berndt, Hervé Ghesquières, James McKay, Sophia S. Wang, Alexandra Nieters, David Cox, Alain Monnereau, Angela R. Brooks-Wilson, Qing Lan, Mads Melbye, Rebecca D. Jackson, Lauren R. Teras, Mark P. Purdue, Claire M. Vajdic, Demetrius Albanes, Anne Zeleniuch-Jacquotte, Simon Crouch, Yawei Zhang, Susan L. Slager, Xifeng Wu, Karin E. Smedby, Gilles Salles, Christine F. Skibola, Nathaniel Rothman, Stephen J. Chanock, James R. Cerhan. Inherited variants at 3q13.33 and 3p24.1 influences risk of diffuse large B-cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 221.
Endothelium-derived relaxing factor in regulation of basal cardiopulmonary and renal function
Perrella, Mark A. , Hildebrand, F L, Burnett, John C. , Margulies, Kenneth B.

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | December 24, 2017 | Volume: 261 | Issue: 2 | Pages: R323-R328

10.1152/ajpregu.1991.261.2.r323 | PMID 1877690 Get It

The endothelium has emerged as an important modulator of vascular tone by producing both vasodilating and vasoconstricting substances. In vitro studies have demonstrated that endothelial cells produce endothelium-derived relaxing factor (EDRF), which promotes vasodilation via the stimulation of intracellular guanosine 3',5'-cyclic monophosphate (cGMP). However, the role of EDRF in the basal regulation of cardiopulmonary and renal function is not well defined. The present study was therefore designed to assess the function of EDRF by studying two groups of normal anesthetized dogs, of which one received a competitive inhibitor to EDRF generation, NG-monomethyl-L-arginine (L-NMMA; 50 micrograms.kg-1.min-1 iv), and the other received a vehicle. The L-NMMA infusion produced no significant increase in mean arterial pressure but marked increases in systemic, pulmonary, and renal vascular resistances compared with the vehicle group. Although renal blood flow decreased with L-NMMA, no changes were observed in glomerular filtration rate or sodium excretion. Associated with the cardiopulmonary and renal responses with L-NMMA was a modest increase in plasma endothelin (7.9 +/- 1.3 to 10.2 +/- 1.8 pg/ml, P less than 0.05), an endothelium-derived vasoconstrictor. No alteration was observed in plasma or urinary cGMP with EDRF inhibition. These cardiopulmonary and renal responses with L-NMMA may be attributed not only to EDRF inhibition but to an imbalance between endothelium-derived relaxing and contracting factors.
A Comprehensive Methodology for Examining the Impact of Surgical Team Briefings and Debriefings on Teamwork
Hildebrand, Emily A., Oliveira-Gomes, Joao, Blocker, Renaldo C., Law, Katherine E. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | October 18, 2014 | Volume: 58 | Issue: 1 | Pages: 703-707

10.1177/1541931214581164 Get It

The adoptions of briefing and debriefing protocols have evolved from the Joint Commission’s initiative to improve communication and safety in the operating room. Briefing normally occurs prior to incision and is used to discuss and confirm critical information, while debriefing occurs during or after surgery. Debriefing provides a unique opportunity for individuals and teams to immediately reflect on their performance, allowing them to more easily identify errors and develop plans to improve their next performance. Studies have shown that using briefings and debriefings improve communication and teamwork. However, there is still much to learn about the value of both for surgical teams. This paper presents a robust methodology for examining and measuring the impacts of surgical team briefings and debriefings on teamwork. The methodology includes (1) audio/video recording the surgical care process, (2) prospective observations using a validated electronic data collection tool, (3) pre- and post-surgery surveys, and (4) individual surgical team member interviews. The current paper describes the methodology to obtain a robust and comprehensive data set for analyzing the impacts of briefing and debriefing on teamwork; the results of the surgeries recorded using this methodology will be presented in subsequent papers.
Team Briefings in the Gynecological Operating Room
Hildebrand, Emily A., Branaghan, Russell J., Hallbeck, M. Susan , Blocker, Renaldo C., Hallbeck, M Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | October 18, 2014 | Volume: 58 | Issue: 1 | Pages: 753-757

10.1177/1541931214581137 Get It

Briefings are suggested to be an important mechanism for establishing and maintaining cohesive teams. However, there is still much to learn about briefings and how best to design and implement them for surgical teams in the operating room. Currently, there are no formally recognized protocols or methodologies for conducting surgical team briefings. This research reports preliminary findings from an effort to develop a model of team briefings for gynecological surgical teams. Semi-structured interviews were conducted using techniques derived from Applied Cognitive Task Analysis (Millitello & Hutton, 1998) with thirteen surgical team members spanning six different roles including surgeon, surgical resident, registered nurse, certified surgical assistant, certified scrub technician, and anesthesia. Findings reveal that informational needs are consistent across the team but also vary by individual role, illustrating the importance of addressing all stakeholders in potential interventions. Implications for the development of a team briefing model are discussed.
Endothelin has biological actions at pathophysiological concentrations.
Hildebrand, F L, Aarhus, L L, Burnett, John C. , Lerman, Amir

Mayo Clinic

Circulation | June 12, 2012 | Volume: 83 | Issue: 5 | Pages: 1808-1814

10.1161/01.cir.83.5.1808 | PMID 2022031 Get It

BACKGROUND Endothelin is an endothelium-derived peptide that produces sustained contraction of arterial and venous smooth muscle in vitro. Several studies have established endothelin as a systemic, renal, and coronary vasoconstrictor in vivo at pharmacological concentrations. Such concentrations of endothelin were antinatriuretic in association with activation of the renin-angiotensin-aldosterone system. Recent studies have demonstrated that endothelin is present in the plasma and that its plasma concentrations are increased in various pathological states associated with systemic and renal vasoconstriction. To date, it remains unclear if such increases in circulating endothelin are associated with biological activity. Thus, the objective of this study was to determine the biological action of endothelin on cardiorenal and endocrine function through administration of exogenous endothelin, which achieves plasma concentrations that have been reported in various pathophysiological conditions. METHODS AND RESULTS Experiments were conducted in two groups of anesthetized dogs. In group 1, endothelin-1 was infused intravenously at 2.5 ng/kg/ml (n = 6), which produced a doubling of circulating concentrations. Group 2 (n = 8) received saline vehicle to serve as a time control. The current studies demonstrate that a twofold increase in plasma endothelin concentrations did not affect mean blood pressure or coronary blood flow. Heart rate and cardiac output decreased in association with increased renal and systemic vascular resistances and antinatriuresis. CONCLUSIONS The present studies demonstrate that endothelin at pathophysiological plasma concentrations produced by exogenous endothelin has biological action. These studies support a functional role for endogenous endothelin as a potentially pathophysiological vasoconstrictor peptide hormone in the regulation of cardiovascular, renal, and endocrine function.